Imperial College London
Alternate

Professor Toby Maher

Faculty of Medicine, National Heart & Lung Institute

Professor of Interstitial Lung Disease
 
 
 
//

Contact

 

+44 (0)20 7594 2151t.maher

 
 
//

Assistant

 

Ms Georgina Moss +44 (0)20 7594 2151

 
//

Location

 

364Sir Alexander Fleming BuildingSouth Kensington Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Lukey:2020:10.1007/s00259-019-04586-z,
author = {Lukey, PT and Coello, C and Gunn, R and Parker, C and Wilson, FJ and Saleem, A and Garman, N and Costa, M and Kendrick, S and Onega, M and Kang'ombe, AR and Listanco, A and Davies, J and Ramada-Magalhaes, J and Moz, S and Fahy, WA and Maher, TM and Jenkins, G and Passchier, J and Marshall, RP},
doi = {10.1007/s00259-019-04586-z},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
pages = {967--979},
title = {Clinical quantification of the integrin αvβ6 by [18F]FB-A20FMDV2 positron emission tomography in healthy and fibrotic human lung (PETAL Study)},
url = {http://dx.doi.org/10.1007/s00259-019-04586-z},
volume = {47},
year = {2020}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - PURPOSE: The RGD-integrin, αvβ6, plays a role in the pathogenesis of pulmonary fibrosis through activation of transforming growth factor beta (TGFβ). This study sought to quantify expression of αvβ6 in the lungs of healthy humans and subjects with pulmonary fibrosis using the αvβ6-selective [18F]FB-A20FMDV2 PET ligand. METHODS: [18F]FB-A20FMDV2 PET/CT scans were performed in healthy subjects and those with fibrotic lung disease. Standard uptake values (SUV) and volume of distribution (VT) were used to quantify αvβ6 expression. In subjects with fibrotic lung disease, qualitative assessment of the relationship between αvβ6 expression and the distribution of fibrosis on high resolution computed tomography was conducted. RESULTS: A total of 15 participants (6 healthy, 7 with idiopathic pulmonary fibrosis (IPF) and 2 with connective tissue disease (CTD) associated PF) were enrolled. VT and SUV of [18F]FB-A20FMDV2 were increased in the lungs of subjects with pulmonary fibrosis (PF) compared with healthy subjects. Geometric mean VT (95% CI) was 0.88 (0.60, 1.29) mL/cm3 for healthy subjects, and 1.40 (1.22, 1.61) mL/cm3 for subjects with IPF; and SUV was 0.54 (0.36, 0.81) g/mL for healthy subjects and 1.03 (0.86, 1.22) g/mL for subjects with IPF. The IPF/healthy VT ratio (geometric mean, (95% CI of ratio)) was 1.59 (1.09, 2.32) (probability ratio > 1 = 0.988)) and the SUV ratio was 1.91 (1.27, 2.87) (probability ratio > 1 = 0.996). Increased uptake of [18F]FB-A20FMDV2 in PF was predominantly confined to fibrotic areas. [18F]FB-A20FMDV2 measurements were reproducible at an interval of 2 weeks. [18F]FB-A20FMDV2 was safe and well tolerated. CONCLUSIONS: Lung uptake of [18F]FB-A20FMDV2, a measure of expression of the integrin αvβ6, was markedly increased in subjects with PF compared with healthy subjects.
AU  - Lukey,PT
AU  - Coello,C
AU  - Gunn,R
AU  - Parker,C
AU  - Wilson,FJ
AU  - Saleem,A
AU  - Garman,N
AU  - Costa,M
AU  - Kendrick,S
AU  - Onega,M
AU  - Kang'ombe,AR
AU  - Listanco,A
AU  - Davies,J
AU  - Ramada-Magalhaes,J
AU  - Moz,S
AU  - Fahy,WA
AU  - Maher,TM
AU  - Jenkins,G
AU  - Passchier,J
AU  - Marshall,RP
DO  - 10.1007/s00259-019-04586-z
EP  - 979
PY  - 2020///
SN  - 0340-6997
SP  - 967
TI  - Clinical quantification of the integrin αvβ6 by [18F]FB-A20FMDV2 positron emission tomography in healthy and fibrotic human lung (PETAL Study)
T2  - European Journal of Nuclear Medicine and Molecular Imaging
UR  - http://dx.doi.org/10.1007/s00259-019-04586-z
UR  - https://www.ncbi.nlm.nih.gov/pubmed/31814068
UR  - https://link.springer.com/article/10.1007%2Fs00259-019-04586-z
UR  - http://hdl.handle.net/10044/1/75685
VL  - 47
ER  -
Download